4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 5c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.63), $0.05 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $1.27 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Piper Sandler Reiterates Overweight Rating on Coca-Cola (KO), 'best-in-class execution'
• Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses